Nucleic Acids

Total RNA was prepared from cell line WM1026. WM1026 is a metastatic human melanoma cell line that displays pigmented and dendritic morphology. This cell line was established from a lymph node metastases of a patient. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell is wild type for PTEN, N-RAS, c-KIT, and CDK4. WM1026 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM115. WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm.This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM115. WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm.This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM115. WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm.This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM115. WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm.This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM115. WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm.This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM115. WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm.This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM1158. WM1158 is a metastatic human melanoma cell line with mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including mutated and hemizygous PTEN deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1158 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM1158. WM1158 is a metastatic human melanoma cell line with mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including mutated and hemizygous PTEN deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1158 cells produce xenograft tumors when injected into immunocompromised mice.